Business Combinations, Dispositions and Other Strategic Investments (Tables)

12 Months Ended

Dec. 31, 2015

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]

Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date (amounts in thousands, except per share data):

	For the Year Ended December 31,
	2015		2014
Revenue	$	985,077	$	696,637
Net income from continuing operations	149,522		25,843
Net income from continuing operations per share	$	1.19	$	0.21

ECR Pharmaceuticals Divestiture [Member]

Business Acquisition [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Calculation of gain/from ECR Divestiture (in millions)
Consideration received	$	41.0
Intangible assets divested	(29.8		)
Goodwill divested	(14.2		)
Other assets divested	(1.2		)
Assumed liabilities divested	5.1
Pre-Tax Gain recognized	$	0.9

Watson Product [Member]

Business Acquisition [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Calculation of gain from Watson product disposition (in millions)
Consideration received	$	16.8
Intangible assets disposed	(5.9		)
Goodwill disposed	(1.1		)
Other assets disposed	(1.3		)
Pre-Tax gain recognized	$	8.5

Excelvision [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Akorn AG acquisition and the fair values of the acquired assets and assumed liabilities (in millions of USD) as of the acquisition date adjusted in accordance with GAAP.

Consideration:
Amount of cash paid	$	25.9
Outstanding amount payable to Fareva	2.5
Total consideration at closing	$	28.4
Recognized amounts of identifiable assets acquired:
Cash and cash equivalents	$	1.2
Accounts receivable	3.4
Inventory	4.2
Other current assets	0.9
Property and equipment	26.6
Total assets acquired	36.3
Assumed current liabilities	(1.7		)
Assumed non-current liabilities	(3.9		)
Deferred tax liabilities	(1.4		)
Total liabilities assumed	(7.0		)
Bargain purchase gain	(0.9		)
Fair value of assets acquired	$	28.4

Lloyd Animal Health Products [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Lloyd Acquisition and the fair values of the acquired assets and assumed liabilities (in millions) as of the acquisition date adjusted in accordance with GAAP.

Consideration:
Amount of cash paid	$	16.1
Fair value of contingent payment	1.9
Total consideration at closing	$	18.0
Recognized amounts of identifiable assets acquired:
Accounts receivable	0.1
Inventory	2.5
Product licensing rights	10.0
IPR&D	5.5
Accounts payable assumed	(0.1		)
Fair value of assets acquired	$	18.0

Xopenex Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Xopenex Acquisition and the fair values of the acquired assets and assumed liabilities (in millions) as of the acquisition date adjusted in accordance with GAAP.  

Consideration:
Amount of cash paid	$	41.5
Product returns and reserves assumed	3.5
Total consideration at closing	$	45.0
Recognized amounts of identifiable assets acquired:
Accounts Receivable, net (product returns and reserves assumed)	(3.5		)
Inventory	6.3
Product licensing rights	38.7
Fair value of net assets acquired	$	41.5

VersaPharm [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the VersaPharm Acquisition and the fair values of the acquired assets and assumed liabilities (in millions) as of the acquisition date adjusted in accordance with GAAP.

Consideration:	Fair Valuation
Amount of cash paid to VersaPharm stockholders	$	322.7
Amount of cash paid to vested VersaPharm option holders	14.2
Amounts paid to escrow accounts	10.3
Transaction expenses paid for previous owners of VersaPharm	3.4
Total consideration paid at closing	350.6
VersaPharm debt paid off through closing cash	82.4
Total cash paid at closing	$	433.0

Recognized amounts of identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	$	0.1
Accounts receivable	3.1
Inventory	21.0
Other current assets	2.8
Property and equipment	1.5
Trademarks	1.0
Product licensing rights	250.8
Intangibles, other	5.2
IPR&D	212.3
Goodwill	100.0
Total assets acquired	$	597.8
Assumed current liabilities	(12.2		)
Assumed non-current liabilities	(81.8		)
Deferred tax liabilities	(153.2		)
Total liabilities assumed	$	(247.2	)
	$	350.6

Hi Tech Pharmacal [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Hi-Tech Acquisition and the fair values of the acquired assets and assumed liabilities (in millions) as of the acquisition date adjusted in accordance with GAAP.  

Consideration:	Fair Valuation
Amount of cash paid to Hi-Tech shareholders	$	605.0
Amount of cash paid to vested Hi-Tech option holders	40.5
Amount of cash paid to key executives under single-trigger separation payments upon change-in-control	4.1
	$	649.6

Recognized amounts of identifiable assets acquired and liabilities assumed:	Fair Valuation
Cash and cash equivalents	$	89.7
Accounts receivable	48.6
Inventory	52.4
Other current assets	34.0
Property and equipment	45.2
Product licensing rights	339.6
IPR&D	9.4
Customer Relationships	0.3
Trademarks	5.5
Goodwill	171.3
Other non-current assets	0.6
Total assets acquired	$	796.6
Assumed current liabilities	(22.6		)
Assumed non-current liabilities	(3.3		)
Deferred tax liabilities	(121.1		)
Total liabilities assumed	$	(147.0	)
	$	649.6

Betimol Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Betimol Acquisition and the fair values of the acquired assets and assumed liabilities (in millions) as of the acquisition date adjusted in accordance with GAAP.

Betimol Acquisition:
Consideration paid in cash at closing	$	7.5
Purchase consideration payable	4.0
	$	11.5
Fair value of acquired assets:
U.S. NDA rights to Betimol®	$	11.4
Favorable supply agreement	0.1
	$	11.5

Merck Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table sets forth the consideration paid for the Merck Acquisition and the fair values of the assets acquired and the liabilities assumed (in millions):

Product rights:
AzaSite®	$	13.8
Cosopt®	21.6
Cosopt® PF	20.3
Product rights total	$	55.7
Prepaid expenses	0.1
Deferred tax assets, net	0.7
Total fair value of acquired assets	$	56.5
Consideration paid	$	52.8
Gain from bargain purchase	$	3.7